First veterinary commercial sale of the SRT-100 outside the
“Whether for treating small animals like cats, dogs, turtles and birds, or large ones like horses, our technology is a valuable addition to leading veterinary practices worldwide. With great technology in the hands of great doctors, the benefits of our SRT-100 System in this vertical are clear. Our advanced technology helps keep skilled practitioners at the top of their field, while their patients benefit from a non-invasive option with no pain, no anesthesia, fast recovery and no fear,” said
“The veterinary channel represents a large and exciting incremental growth opportunity for Sensus, as thought-leading institutions with tremendous knowledge and experience like CSU and now Chavat Da’at demonstrate the utility and versatility of our products. These leaders are exploring and expanding the veterinary indications for radiotherapy, while making treatments increasingly available and affordable to many more pet owners,” he added.
About
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to maintain profitability; our ability to sell the number of SRT units we anticipate for the balance of 2024; the possibility that inflationary pressures continue to impact our sales; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in
To date, we do not expect that the
Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the
Contact:
LHA Investor Relations
212-838-3777
kgolodetz@lhai.com
# # #
Source:
2024 GlobeNewswire, Inc., source